NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Forecast, Price & News

$1.15

+0.04 (+3.60%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.10
▼
$1.16
50-Day Range: $1.11
▼
$1.76
52-Week Range: $1.07
▼
$6.42

Volume: 1.99 million shs
Average Volume: 2.41 million shs
Market Capitalization: $197.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.91

Sangamo Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 675.2% Upside
$8.91 Price Target
Short Interest: Healthy
10.25% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.77) to ($1.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

506th out of 983 stocks

Biological Products, Except Diagnostic Industry

85th out of 164 stocks

3.3

Analyst's Opinion

Consensus Rating
Sangamo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $8.91, Sangamo Therapeutics has a forecasted upside of 675.2% from its current price of $1.15.
Amount of Analyst Coverage
Sangamo Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
10.25% of the outstanding shares of Sangamo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sangamo Therapeutics has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Sangamo Therapeutics has recently decreased by 12.91%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sangamo Therapeutics does not currently pay a dividend.
Dividend Growth
Sangamo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGMO.

3.2

News and Social Media Coverage

News Sentiment
Sangamo Therapeutics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Sangamo Therapeutics this week, compared to 2 articles on an average week.
Search Interest
23 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Sangamo Therapeutics is held by insiders.
Percentage Held by Institutions
59.34% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sangamo Therapeutics are expected to decrease in the coming year, from ($0.77) to ($1.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sangamo Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sangamo Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sangamo Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Stock News Headlines

May 22, 2023 | finance.yahoo.com

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease

May 18, 2023 | finance.yahoo.com

Industry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52%

June 4, 2023 | Behind the Markets (Ad)

Our #1 Laser Stock for May

The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>

May 16, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

May 14, 2023 | americanbankingnews.com

Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $9.07

May 13, 2023 | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to Hold by StockNews.com

May 13, 2023 | americanbankingnews.com

Truist Financial Trims Sangamo Therapeutics (NASDAQ:SGMO) Target Price to $8.00

May 11, 2023 | msn.com

Truist Securities Maintains Sangamo Therapeutics (SGMO) Buy Recommendation

June 4, 2023 | Behind the Markets (Ad)

Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"

Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>

May 2, 2023 | finance.yahoo.com

Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

May 2, 2023 | finance.yahoo.com

Analysts Just Made A Huge Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

May 2, 2023 | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Given New $5.00 Price Target at HC Wainwright

May 1, 2023 | bizjournals.com

Sangamo Therapeutics chopping 120 jobs after Biogen, Novartis exit deals

May 1, 2023 | msn.com

Sangamo Therapeutics's Return On Capital Employed Overview

May 1, 2023 | msn.com

HC Wainwright & Co. Maintains Sangamo Therapeutics (SGMO) Buy Recommendation

May 1, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Sangamo Therapeutics

April 30, 2023 | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Cut to $3.90 by Analysts at Stifel Nicolaus

April 29, 2023 | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Rating Lowered to Underperform at Bank of America

April 28, 2023 | msn.com

B of A Securities Downgrades Sangamo Therapeutics (SGMO)

April 27, 2023 | msn.com

Soon After Novartis & Biogen Walked Away From Neurology Drug Partnerships, Sangamo Announces Major Restructuring

April 26, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

April 25, 2023 | finance.yahoo.com

Biogen shifts gene therapy focus as it builds $200M facility in RTP

April 25, 2023 | americanbankingnews.com

Sangamo Therapeutics (SGMO) to Release Earnings on Wednesday

April 21, 2023 | finance.yahoo.com

Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?

April 21, 2023 | finance.yahoo.com

Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?

April 19, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

April 19, 2023 | americanbankingnews.com

Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $12.80

See More Headlines

SGMO Price History

30 days | 90 days | 365 days | Advanced Chart

SGMO Company Calendar

Last Earnings: 2/22/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SGMO
CUSIP: 80067710
CIK: 1001233
Web: www.sangamo.com
Phone: (510) 970-6000
Fax: 510-236-8951
Employees: 431
Year Founded: 1995

Price Target and Rating

Average Stock Price Forecast: $8.91
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +675.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-192,280,000.00
Net Margins: -52.76%
Pretax Margin: -52.53%
Return on Equity: -40.44%
Return on Assets: -22.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.93
Quick Ratio: 3.93

Sales & Book Value

Annual Sales: $111.30 million
Price / Sales: 1.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.95 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 171,830,000
Free Float: 166,671,000
Market Cap: $197.60 million
Optionable: Optionable
Beta: 1.07

Social Links

Key Executives

Alexander D. Macrae
President, Chief Executive Officer & Director

Mark D. McClung
Chief Operating Officer & Executive Vice President

Prathyusha Durabaibu
Chief Financial & Accounting Officer, Senior VP

R. Andrew Ramelmeier
Executive Vice President-Technical Operations

Jason D. Fontenot
Chief Scientific Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGMO Stock - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGMO shares.
View SGMO analyst ratings or view top-rated stocks.
What is Sangamo Therapeutics' stock price forecast for 2023?: 5 brokerages have issued 12-month price targets for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $16.00. On average, they expect the company's share price to reach $8.91 in the next year. This suggests a possible upside of 675.2% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.
How have SGMO shares performed in 2023?: Sangamo Therapeutics' stock was trading at $3.14 at the start of the year. Since then, SGMO shares have decreased by 63.4% and is now trading at $1.15.
View the best growth stocks for 2023 here.
When is Sangamo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SGMO earnings forecast.
How were Sangamo Therapeutics' earnings last quarter?: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings data on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. The biopharmaceutical company earned $27.23 million during the quarter, compared to analyst estimates of $26.86 million. Sangamo Therapeutics had a negative net margin of 52.76% and a negative trailing twelve-month return on equity of 40.44%. The firm's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) EPS.
What ETFs hold Sangamo Therapeutics' stock?: ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA) and SPDR S&P Biotech ETF (XBI).
What guidance has Sangamo Therapeutics issued on next quarter's earnings?: Sangamo Therapeutics issued an update on its first quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $158.00 million-$158.00 million.
What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?: 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).
What is Sangamo Therapeutics' stock symbol?: Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
Who are Sangamo Therapeutics' major shareholders?: Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.22%), Wasatch Advisors LP (7.94%), State Street Corp (5.21%), Credit Suisse AG (2.23%), Dimensional Fund Advisors LP (1.92%) and Renaissance Technologies LLC (1.88%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends.
How do I buy shares of Sangamo Therapeutics?: Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sangamo Therapeutics' stock price today?: One share of SGMO stock can currently be purchased for approximately $1.15.
How much money does Sangamo Therapeutics make?: Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $197.60 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.
How many employees does Sangamo Therapeutics have?: The company employs 431 workers across the globe.
How can I contact Sangamo Therapeutics?: Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial